|
Oct 1
|
Wall Street Analysts Think Corcept (CORT) Could Surge 41.31%: Read This Before Placing a Bet
|
|
Oct 1
|
Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year?
|
|
Sep 30
|
Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast
|
|
Sep 25
|
Does Corcept Therapeutics (CORT) Have a Long Runway for Growth?
|
|
Sep 19
|
Corcept (CORT) Moves 6.5% Higher: Will This Strength Last?
|
|
Aug 28
|
Corcept (CORT) Down 4% Since Last Earnings Report: Can It Rebound?
|
|
Aug 27
|
Corcept (CORT) Upgraded to Buy: Here's Why
|
|
Aug 9
|
3 US Growth Companies With High Insider Ownership
|
|
Jul 22
|
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
|
|
Jun 26
|
Corcept (CORT) Shares Rise 20% in Three Months: Here's Why
|
|
Jun 24
|
Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions
|
|
Jun 19
|
What Makes Corcept Therapeutics (CORT) a Good Investment Bet?
|
|
Jun 14
|
Corcept Therapeutics (CORT) is a Top-Ranked Momentum Stock: Should You Buy?
|
|
Jun 13
|
Teva sues Corcept over mifepristone 'monopoly' for rare disorder
|
|
Jun 11
|
Insider-Owned Growth Companies To Watch On US Exchanges In June 2024
|
|
Jun 3
|
Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome)
|
|
May 31
|
Corcept (CORT) Up 24.5% Since Last Earnings Report: Can It Continue?
|
|
May 31
|
Insider Sale: Chief Development Officer William Guyer Sells 30,000 Shares of Corcept ...
|
|
May 29
|
Corcept (CORT) Rises as Cushing's Syndrome Study Meets Goal
|
|
May 28
|
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)
|